---
title: "After Novo Nordisk AS announced it would acquire Akero Therapeutics for up to $5.2 billion, the comp"
description: "After Novo Nordisk AS announced it would acquire Akero Therapeutics for up to $5.2 billion, the company's stock price rose by 17%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260473854.md"
published_at: "2025-10-09T13:31:40.000Z"
---

# After Novo Nordisk AS announced it would acquire Akero Therapeutics for up to $5.2 billion, the comp

> After Novo Nordisk AS announced it would acquire Akero Therapeutics for up to $5.2 billion, the company's stock price rose by 17%

After Novo Nordisk AS announced it would acquire Akero Therapeutics for up to $5.2 billion, the company's stock price rose by 17%

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/en/news/276056741.md) |
| Savvy Advisors Inc. Purchases 22,138 Shares of Novo Nordisk A/S $NVO | Savvy Advisors Inc. increased its stake in Novo Nordisk A/S by 83.0% in Q3, acquiring 22,138 shares, bringing its total  | [Link](https://longbridge.com/en/news/275761183.md) |
| Novo Nordisk CFO Karsten Munk Knudsen Sells Shares Worth Over DKK 8.3 Million | Novo Nordisk A/S announced that CFO Karsten Munk Knudsen sold 26,246 shares for DKK 8.3 million at DKK 315.60 each and 3 | [Link](https://longbridge.com/en/news/275652909.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/en/news/275789396.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/en/news/275719942.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.